

Cecilia Linde

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6721168/publications.pdf>

Version: 2024-02-01

166
papers

34,702
citations

57758

44
h-index

6996

154
g-index

170
all docs

170
docs citations

170
times ranked

27077
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2016, 37, 2129-2200.	2.2	13,008
2	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2016, 18, 891-975.	7.1	5,272
3	Effects of Multisite Biventricular Pacing in Patients with Heart Failure and Intraventricular Conduction Delay. New England Journal of Medicine, 2001, 344, 873-880.	27.0	2,560
4	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2013, 34, 2281-2329.	2.2	2,176
5	Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). European Heart Journal, 2005, 26, 1115-1140.	2.2	1,986
6	Randomized Trial of Cardiac Resynchronization in Mildly Symptomatic Heart Failure Patients and in Asymptomatic Patients With Left Ventricular Dysfunction and Previous Heart Failure Symptoms. Journal of the American College of Cardiology, 2008, 52, 1834-1843.	2.8	1,060
7	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace, 2013, 15, 1070-1118.	1.7	908
8	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2021, 42, 3427-3520.	2.2	899
9	Long-term benefits of biventricular pacing in congestive heart failure: results from the Multisite STimulation in cardiomyopathy (MUSTIC) study. Journal of the American College of Cardiology, 2002, 40, 111-118.	2.8	855
10	An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. European Heart Journal, 2013, 34, 3547-3556.	2.2	410
11	Prevention of Disease Progression by Cardiac Resynchronization Therapy in Patients With Asymptomatic or Mildly Symptomatic Left Ventricular Dysfunction. Journal of the American College of Cardiology, 2009, 54, 1837-1846.	2.8	316
12	Effect of QRS Duration and Morphology on Cardiac Resynchronization Therapy Outcomes in Mild Heart Failure. Circulation, 2012, 126, 822-829.	1.6	279
13	2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management: A registered branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society; and in collaboration with the Heart Failure Society of America (HFSA), the American Society of Echocardiography (ASE), the American Heart Association (AHA), the European Association of Echocardiography (FAE) of the ESC and the Heart		

#	ARTICLE	IF	CITATIONS
19	Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. <i>European Heart Journal</i> , 2013, 34, 529-539.	2.2	132
20	Long-term improvements in quality of life by biventricular pacing in patients with chronic heart failure: results from the MULTISITE STimulation In Cardiomyopathy Study (MUSTIC). <i>American Journal of Cardiology</i> , 2003, 91, 1090-1095.	1.6	122
21	Association between cardiovascular vs. noncardiovascular comorbidities and outcomes in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 992-1001.	7.1	119
22	Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	107
23	CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients "who is doing what to whom and how?". <i>European Journal of Heart Failure</i> , 2018, 20, 1039-1051.	7.1	107
24	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. <i>European Journal of Heart Failure</i> , 2020, 22, 2349-2369.	7.1	101
25	Cardiac Resynchronization Therapy in Asymptomatic or Mildly Symptomatic Heart Failure Patients in Relation to Etiology. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1826-1831.	2.8	96
26	Current use of implantable electrical devices in Sweden: data from the Swedish pacemaker and implantable cardioverter-defibrillator registry. <i>Europace</i> , 2015, 17, 69-77.	1.7	94
27	Cardiac resynchronization therapy (CRT): Clinical trials, guidelines, and target populations. <i>Heart Rhythm</i> , 2012, 9, S3-S13.	0.7	93
28	Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 129-136.	4.1	90
29	Association between demographic, organizational, clinical, and socioeconomic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2017, 19, 1270-1279.	7.1	86
30	Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure "the REsynchronization reVERses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. <i>American Heart Journal</i> , 2006, 151, 288-294.	2.7	85
31	The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: Results of the REVERSE study. <i>Heart Rhythm</i> , 2015, 12, 524-530.	0.7	85
32	The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis. <i>European Journal of Heart Failure</i> , 2018, 20, 780-791.	7.1	81
33	Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure. <i>Circulation</i> , 2019, 140, 1530-1539.	1.6	78
34	New echocardiographic predictors of clinical outcome in patients presenting with heart failure and a preserved left ventricular ejection fraction: a subanalysis of the Ka (Karolinska) Ren (Rennes) Study. <i>European Journal of Heart Failure</i> , 2015, 17, 680-688.	7.1	77
35	Imaging predictors of response to cardiac resynchronization therapy: left ventricular work asymmetry by echocardiography and septal viability by cardiac magnetic resonance. <i>European Heart Journal</i> , 2020, 41, 3813-3823.	2.2	75
36	Indications for Cardiac Resynchronization Therapy. <i>JACC: Heart Failure</i> , 2018, 6, 308-316.	4.1	68

#	ARTICLE	IF	CITATIONS
37	Spatial detection of fetal marker genes expressed at low level in adult human heart tissue. <i>Scientific Reports</i> , 2017, 7, 12941.	3.3	62
38	Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK. <i>ESC Heart Failure</i> , 2019, 6, 280-290.	3.1	57
39	Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review. <i>European Heart Journal</i> , 2015, 36, 2780-2789.	2.2	55
40	Gender, underutilization of cardiac resynchronization therapy, and prognostic impact of QRS prolongation and left bundle branch block in heart failure. <i>Europace</i> , 2015, 17, 424-431.	1.7	55
41	Reduction of hospital days by biventricular pacing. <i>European Journal of Heart Failure</i> , 2000, 2, 399-406.	7.1	54
42	Age, prognostic impact of <scp>QRS</scp> prolongation and left bundle branch block, and utilization of cardiac resynchronization therapy: findings from 14 713 patients in the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2014, 16, 1073-1081.	7.1	54
43	Implantable Defibrillators Improve Survival in Patients With Mildly Symptomatic Heart Failure Receiving Cardiac Resynchronization Therapy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013, 6, 1163-1168.	4.8	51
44	Haematological indices as predictors of atrial fibrillation following isolated coronary artery bypass grafting, valvular surgery, or combined procedures: a systematic review with meta-analysis. <i>Kardiologia Polska</i> , 2018, 76, 107-118.	0.6	50
45	Rationale and design of the Karolinskaâ€Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2009, 11, 198-204.	7.1	47
46	The burden of proof: The current state of atrial fibrillation prevention and treatment trials. <i>Heart Rhythm</i> , 2017, 14, 763-782.	0.7	47
47	Metabolomic Profile in HFpEF vs HFrEF Patients. <i>Journal of Cardiac Failure</i> , 2020, 26, 1050-1059.	1.7	46
48	Prediction of New-Onset and Recurrent Atrial Fibrillation by Complete Blood Count Tests: A Comprehensive Systematic Review with Meta-Analysis. <i>Medical Science Monitor Basic Research</i> , 2017, 23, 179-222.	2.6	44
49	Realâ€World Associations of Reninâ€Angiotensinâ€Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With Newâ€Onset Chronic Kidney Disease or Heart Failure in the United Kingdom. <i>Journal of the American Heart Association</i> , 2019, 8, e012655.	3.7	44
50	Metaâ€analysis of symptomatic response attributable to the pacing component of cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2013, 15, 1419-1428.	7.1	40
51	Baseline characteristics of patients with heart failure and preserved ejection fraction included in the Karolinska Rennes (KaRen) study. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 112-121.	1.6	40
52	ST2 in heart failure with preserved and reduced ejection fraction. <i>Scandinavian Cardiovascular Journal</i> , 2019, 53, 21-27.	1.2	40
53	A systematic review and meta-analysis of beta-blockers and reninâ€angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer. <i>European Heart Journal</i> , 2022, 43, 2562-2569.	2.2	39
54	HFpEF and HFrEF exhibit different phenotypes as assessed by leptin and adiponectin. <i>International Journal of Cardiology</i> , 2017, 228, 709-716.	1.7	38

#	ARTICLE	IF	CITATIONS
55	Current challenges for clinical trials of cardiovascular medical devices. <i>International Journal of Cardiology</i> , 2014, 175, 30-37.	1.7	37
56	Opportunity to Increase Life Span in Narrow QRS Cardiac Resynchronization Therapy Recipients by Deactivating Ventricular Pacing. <i>JACC: Heart Failure</i> , 2015, 3, 327-336.	4.1	37
57	Transcriptomics of cardiac biopsies reveals differences in patients with or without diagnostic parameters for heart failure with preserved ejection fraction. <i>Scientific Reports</i> , 2019, 9, 3179.	3.3	35
58	How to Evaluate Quality-of-Life in Pacemaker Patients: Problems and Pitfalls. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1996, 19, 391-397.	1.2	34
59	Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With Cardiac Resynchronization. <i>JACC: Heart Failure</i> , 2017, 5, 169-178.	4.1	34
60	Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink. <i>BMC Nephrology</i> , 2018, 19, 211.	1.8	34
61	Redefining the Classifications of Response to Cardiac Resynchronization Therapy. <i>JACC: Clinical Electrophysiology</i> , 2021, 7, 871-880.	3.2	33
62	Trials of implantable monitoring devices in heart failure: which design is optimal?. <i>Nature Reviews Cardiology</i> , 2014, 11, 576-585.	13.7	31
63	The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: who benefits the most?. <i>European Heart Journal</i> , 2015, 36, 1676-1688.	2.2	31
64	Reflections on EchoCRT: sound guidance on QRS duration and morphology for CRT?: Figure 1. <i>European Heart Journal</i> , 2015, 36, 1948-1951.	2.2	30
65	Cardiac resynchronization therapy in chronic heart failure with moderately reduced left ventricular ejection fraction: Lessons from the Multicenter InSync Randomized Clinical Evaluation MIRACLE EF study. <i>International Journal of Cardiology</i> , 2016, 202, 349-355.	1.7	28
66	New York Heart Association functional class, QRS duration, and survival in heart failure with reduced ejection fraction: implications for cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2017, 19, 366-376.	7.1	28
67	Patient reported outcome in HFpEF: Sex-specific differences in quality of life and association with outcome. <i>International Journal of Cardiology</i> , 2018, 267, 128-132.	1.7	28
68	Myeloperoxidase and related biomarkers are suggestive footprints of endothelial microvascular inflammation in HFpEF patients. <i>ESC Heart Failure</i> , 2020, 7, 1534-1546.	3.1	28
69	Impact of Ejection Fraction on the Clinical Response to Cardiac Resynchronization Therapy in Mild Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 1180-1189.	3.9	27
70	Predictors of short-term clinical response to cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2017, 19, 1056-1063.	7.1	27
71	HFpEF and HFrEF Display Different Phenotypes as Assessed by IGF-1 and IGFBP-1. <i>Journal of Cardiac Failure</i> , 2017, 23, 293-303.	1.7	25
72	Pacing for hypertrophic obstructive cardiomyopathy: an update and future directions. <i>Europace</i> , 2018, 20, 908-920.	1.7	25

#	ARTICLE	IF	CITATIONS
73	Baseline Characteristics of Patients Randomized in the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) Study. <i>Congestive Heart Failure</i> , 2008, 14, 66-74.	2.0	24
74	The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease. <i>BMC Nephrology</i> , 2019, 20, 31.	1.8	24
75	Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE). <i>Journal of the American Heart Association</i> , 2015, 4, e002054.	3.7	23
76	Patient profile and outcomes associated with follow-up in specialty vs. primary care in heart failure. <i>ESC Heart Failure</i> , 2022, 9, 822-833.	3.1	23
77	European Cardiac Resynchronization Therapy Survey II: rationale and design. <i>Europace</i> , 2015, 17, 137-141.	1.7	22
78	The transition from hypertension to hypertensive heart disease and heart failure: the PREFERS Hypertension study. <i>ESC Heart Failure</i> , 2020, 7, 737-746.	3.1	22
79	Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2015, 17, 135-143.	7.1	21
80	European Society of Cardiology Quality Indicators for the care and outcomes of cardiac pacing: developed by the Working Group for Cardiac Pacing Quality Indicators in collaboration with the European Heart Rhythm Association of the European Society of Cardiology. <i>Europace</i> , 2022, 24, 165-172.	1.7	20
81	History of electrical therapy for the heart. <i>Country Review Ukraine</i> , 2007, 9, I3-I10.	0.8	19
82	Comparison of Prognostic Usefulness of Serum Insulin-Like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction. <i>American Journal of Cardiology</i> , 2018, 121, 1558-1566.	1.6	19
83	Cardiac resynchronization therapy pacemaker or cardiac resynchronization therapy defibrillator: what determines the choice? findings from the ESC CRT Survey II. <i>Europace</i> , 2019, 21, 918-927.	1.7	19
84	Cardiac Resynchronization Therapy in Patients With New York Heart Association Class I and II Heart Failure. <i>Circulation</i> , 2010, 122, 1037-1043.	1.6	18
85	Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2019, 6, 830-839.	3.1	18
86	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. <i>Europace</i> , 2021, 23, 1324-1342.	1.7	18
87	Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes. <i>International Journal of Cardiology</i> , 2015, 189, 6-11.	1.7	17
88	Rationale and design of the PREFERS (Preserved and Reduced Ejection Fraction) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 147 T Stockholm county of 2.1 million inhabitants. <i>European Journal of Heart Failure</i> , 2016, 18, 1287-1297.	7.1	17
89	Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study. <i>Open Heart</i> , 2015, 2, e000260.	2.3	16
90	Electrical management of heart failure: from pathophysiology to treatment. <i>European Heart Journal</i> , 2022, 43, 1917-1927.	2.2	16

#	ARTICLE	IF	CITATIONS
91	Risk stratification with echocardiographic biomarkers in heart failure with preserved ejection fraction: the media echo score. ESC Heart Failure, 2021, 8, 1827-1839.	3.1	15
92	N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum. International Journal of Cardiology, 2019, 287, 66-72.	1.7	14
93	Future research prioritization in cardiac resynchronization therapy. American Heart Journal, 2020, 223, 48-58.	2.7	13
94	Predictors of long-term outcome in heart failure with preserved ejection fraction: a follow-up from the <sc>KaRen</sc> study. ESC Heart Failure, 2021, 8, 4243-4254.	3.1	13
95	The Importance of Early Evaluation after Cardiac Resynchronization Therapy to Redefine Response: Pooled Individual Patient Analysis from Five Prospective Studies. Heart Rhythm, 2021, , .	0.7	13
96	Sex-Related Procedural Aspects and Complications in CRT Survey II. JACC: Clinical Electrophysiology, 2019, 5, 1048-1058.	3.2	12
97	Women and Arrhythmias. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 1550-1560.	1.2	11
98	Myocardial micro-biopsy procedure for molecular characterization with increased precision and reduced trauma. Scientific Reports, 2020, 10, 8029.	3.3	11
99	Circulating neuregulin1 in heart failure with preserved and reduced left ventricular ejection fraction. ESC Heart Failure, 2020, 7, 445-455.	3.1	11
100	Importance of Systematic Right Ventricular Assessment in Cardiac Resynchronization Therapy Candidates: A Machine Learning Approach. Journal of the American Society of Echocardiography, 2021, 34, 494-502.	2.8	11
101	Effects of Spinal Cord Stimulation on Cardiac Sympathetic Nerve Activity in Patients with Heart Failure. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 504-513.	1.2	10
102	Cost effectiveness of implementing ESC guidelines for treatment of iron deficiency in heart failure in the Nordic countries. Scandinavian Cardiovascular Journal, 2018, 52, 348-355.	1.2	10
103	Importance of structural heart disease and diastolic dysfunction in heart failure with preserved ejection fraction assessed according to the ESC guidelines - A substudy in the Ka (Karolinska) Ren (Rennes) study. International Journal of Cardiology, 2019, 274, 202-207.	1.7	10
104	Cardiac resynchronization therapy with or without defibrillator in patients with heart failure. Europace, 2022, 24, 48-57.	1.7	10
105	Predictors of primary prevention implantable cardioverter-defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and all-cause mortality. European Journal of Heart Failure, 2022, 24, 1212-1222.	7.1	10
106	Cardiac resynchronization therapy: clinical results and evolution of candidate selection. Country Review Ukraine, 2007, 9, 194-1106.	0.8	9
107	Adherence to ESC cardiac resynchronization therapy guidelines: findings from the ESC CRT Survey II. Europace, 2020, 22, 932-938.	1.7	8
108	Pace and ablate better than drugs in patients with heart failure and atrial fibrillation: lessons from the APAF-CRT mortality trial. European Heart Journal, 2021, 42, 4740-4742.	2.2	8

#	ARTICLE	IF	CITATIONS
109	Left atrial strain is a predictor of left ventricular systolic and diastolic reverse remodelling in CRT candidates. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 1373-1382.	1.2	8
110	Cardiac resynchronization therapy in mild heart failure. <i>Europace</i> , 2009, 11, v72-v76.	1.7	7
111	Increased iron absorption in patients with chronic heart failure and iron deficiency. <i>Journal of Cardiac Failure</i> , 2020, 26, 440-443.	1.7	7
112	Implantable cardioverter-defibrillator treatment and resynchronisation in heart failure. <i>British Heart Journal</i> , 2004, 90, 231-234.	2.1	6
113	Cardiac Resynchronization Therapy Follow-up. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 797-807.	1.7	6
114	Cardiac resynchronization therapy: results, challenges and perspectives for the future. <i>Scandinavian Cardiovascular Journal</i> , 2016, 50, 282-292.	1.2	6
115	The prognostic significance of atrial fibrillation in heart failure with preserved ejection function: insights from KaRen, a prospective and multicenter study. <i>Heart and Vessels</i> , 2017, 32, 735-749.	1.2	6
116	The <i>European Heart Journal</i> : leading the fight to reduce the global burden of cardiovascular disease. <i>European Heart Journal</i> , 2020, 41, 3113-3116.	2.2	6
117	Reorganization of heart failure management and improved outcome – the 4D HF Project. <i>Scandinavian Cardiovascular Journal</i> , 2021, 55, 1-8.	1.2	6
118	Increase in paced heart rate reduces muscle sympathetic nerve activity in heart failure patients treated with cardiac resynchronization therapy. <i>Europace</i> , 2015, 17, 439-446.	1.7	5
119	Spinal cord stimulation in heart failure: effect on disease-associated biomarkers. <i>European Journal of Heart Failure</i> , 2017, 19, 283-286.	7.1	5
120	The Impact of the PR Interval in Patients Receiving Cardiac Resynchronization Therapy. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 818-826.	3.2	5
121	Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure. <i>Journal of Medical Economics</i> , 2018, 21, 1172-1182.	2.1	5
122	Do Patients With Acute Heart Failure and Preserved Ejection Fraction Have Heart Failure at Follow-Up: Implications of the Framingham Criteria. <i>Journal of Cardiac Failure</i> , 2020, 26, 673-684.	1.7	5
123	Pacing for repeated vagal reflex-mediated syncope: an old problem with a solution. <i>European Heart Journal</i> , 2021, 42, 517-519.	2.2	5
124	Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial. <i>ESC Heart Failure</i> , 2022, 9, 164-177.	3.1	5
125	Quality-of-Life in Pacemaker and Implantable Cardioverter Defibrillator Recipients. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2000, 23, 931-933.	1.2	4
126	When cardiac resynchronization therapy may be harmful: time to wake up. <i>Europace</i> , 2015, 17, 171-173.	1.7	4

#	ARTICLE	IF	CITATIONS
127	Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study. <i>International Journal of Cardiology</i> , 2017, 226, 65-70.	1.7	4
128	CRT-P or CRT-D in heart failure patients: the RESET-CRT projectâ€”a prelude to the randomized controlled RESET-CRT study. <i>European Heart Journal</i> , 2022, 43, 2600-2602.	2.2	4
129	Cardiac Resynchronization Therapy Follow-up. <i>Heart Failure Clinics</i> , 2017, 13, 241-251.	2.1	3
130	Cardiomyopathy and Leftâ€”Bundleâ€”Branchâ€”Block. <i>Journal of the American College of Cardiology</i> , 2018, 71, 318-320.	2.8	3
131	The year in cardiology 2017: arrhythmias and cardiac devices. <i>European Heart Journal</i> , 2018, 39, 434-441.	2.2	3
132	Comparison of current German and European practice in cardiac resynchronization therapy: lessons from the ESC/EHRA/HFA CRT Survey II. <i>Clinical Research in Cardiology</i> , 2020, 109, 832-844.	3.3	3
133	Ambulatory blood pressure monitoring and blood pressure control in patients with coronary artery diseaseâ€”A randomized controlled trial. <i>International Journal of Cardiology: Hypertension</i> , 2021, 8, 100074.	2.2	3
134	OUP accepted manuscript. <i>European Heart Journal</i> , 2022, , .	2.2	3
135	Baseline characteristics of 547 new onset heart failure patients in the PREFERS heart failure study. <i>ESC Heart Failure</i> , 2022, 9, 2125-2138.	3.1	3
136	Pacing in Dilated Cardiomyopathy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1995, 18, 1341-1345.	1.2	2
137	How do patients with previous <scp>RV</scp> pacing respond to upgrading to <scp>CRT</scp>? Important messages for pacemaker and <scp>ICD</scp> followâ€”up. <i>European Journal of Heart Failure</i> , 2014, 16, 1157-1159.	7.1	2
138	Outcome and presentation of heart failure in breast cancer patients: findings from a Swedish register-based study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020, 6, 147-155.	4.0	2
139	Withdrawn as duplicate: Optimized Implementation of cardiac resynchronization therapy â€” a call for action for referral and optimization of care. <i>Europace</i> , 2023, 25, .	1.7	2
140	Prognostic utility of the assessment of diastolic function in patients undergoing cardiac resynchronization therapy. <i>International Journal of Cardiology</i> , 2021, 331, 144-151.	1.7	2
141	Do we differ in terms of indications and demographics in cardiac resynchronisation recipients in Poland? Insights from the European CRT Survey II Registry. <i>Kardiologia Polska</i> , 2019, 77, 40-46.	0.6	2
142	Combipolar Sensing in Dual Chamber Pacing: Is There Still a Need for Bipolar Leads in the Atrium?. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2001, 24, 1664-1671.	1.2	1
143	Celebrating 50 years of electrical therapies for the heart. <i>Country Review Ukraine</i> , 2007, 9, 11-12.	0.8	1
144	Improvement of blood pressure control and physiciansâ€™ management over time in patients with coronary artery disease. <i>Blood Pressure</i> , 2016, 25, 286-291.	1.5	1

#	ARTICLE	IF	CITATIONS
145	FP337RELATIONSHIP BETWEEN HYPERKALAEMIA AND DOWN-TITRATION OR DISCONTINUATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS IN UK PATIENTS WITH CKD. Nephrology Dialysis Transplantation, 2018, 33, i145-i145.	0.7	1
146	Croatian National Data and Comparison with European Practice: Data from the Cardiac Resynchronization Therapy Survey II Multicenter Registry. Cardiology Research and Practice, 2018, 2018, 1-8.	1.1	1
147	Contemporary practice of CRT implantation in scandinavia compared to Europe. Scandinavian Cardiovascular Journal, 2019, 53, 9-13.	1.2	1
148	Second European Society of Cardiology Cardiac Resynchronization Therapy Survey: the Italian cohort. Journal of Cardiovascular Medicine, 2020, 21, 634-640.	1.5	1
149	Response by Schrage et al to Letter Regarding Article, "Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry". Circulation, 2020, 141, e648-e649.	1.6	1
150	Integrated care for atrial fibrillation: time for widespread use. European Heart Journal, 2020, 41, 2845-2847.	2.2	1
151	Cardiac resynchronization therapy in Romania " results from the European Society of Cardiology CRT Survey II. Revista Romana De Cardiologie, 2020, 30, 48-55.	0.1	1
152	Cardiac Resynchronisation Therapy (CRT) Survey II: CRT implantation in Europe and in Switzerland. Swiss Medical Weekly, 2018, 148, w14643.	1.6	1
153	Current clinical practice of cardiac resynchronization therapy in Turkey: reflections from CRT SURVEY-II. Anatolian Journal of Cardiology, 2020, 24, 382-396.	0.9	1
154	Upgrades from Previous Cardiac Implantable Electronic Devices Compared to De Novo Cardiac Resynchronization Therapy Implantations: Results from CRT Survey-II in the Turkish Population.. Turk Kardiyoloji Dernegi Arsivi, 2022, 50, 182-191.	0.2	1
155	Future directions in cardiac resynchronization therapy. Current Heart Failure Reports, 2008, 5, 51-55.	3.3	0
156	Cardiac resynchronization revisited: what is the next step?. European Journal of Heart Failure, 2015, 17, 881-883.	7.1	0
157	Biventricular Stimulation. Journal of the American College of Cardiology, 2016, 67, 2158-2160.	2.8	0
158	FP371RECURRENT HYPERKALAEMIA AND ASSOCIATION WITH LENGTH-OF-STAY AND MORTALITY FOLLOWING HOSPITALISATION: REAL-WORLD EVIDENCE FROM UK PATIENTS WITH CKD. Nephrology Dialysis Transplantation, 2018, 33, i157-i157.	0.7	0
159	The European Society of Cardiology Cardiac Resynchronization Therapy Survey II: A comparison of cardiac resynchronization therapy implantation practice in Europe and France. Archives of Cardiovascular Diseases, 2019, 112, 713-722.	1.6	0
160	The Membership Committee of the ESC. Cardiovascular Research, 2019, 115, e130-e132.	3.8	0
161	Spanish Results of the Second European Cardiac Resynchronization Therapy Survey (CRT-Survey II). Revista Espanola De Cardiologia (English Ed), 2019, 72, 1020-1030.	0.6	0
162	Cardiac resynchronization in Poland " comparable procedural routines? Insights from CRT Survey II. Postepy W Kardiologii Interwencyjnej, 2019, 15, 477-484.	0.2	0

#	ARTICLE	IF	CITATIONS
163	Benchmarking Belgian CRT practice against the rest of Europe: insights from the ESC-CRT survey II. Acta Cardiologica, 2020, 75, 492-496.	0.9	0
164	Quality of life with implanted devices. , 2020, , 893-900.		0
165	Second European Cardiac Resynchronisation Therapy Survey (Crt Survey II): Latvian Data Compared to Europe. Proceedings of the Latvian Academy of Sciences, 2020, 74, 358-365.	0.1	0
166	MO151: A Randomized Controlled Trial of Sodium Zirconium Cyclosilicate Versus Standard of Care for Hyperkalaemia in Chronic Kidney Disease: Phase 4 Continuity Study Design and Rationale. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0